Journal of Clinical and Experimental Ophthalmology
Open Access
ISSN: 2155-9570
ISSN: 2155-9570
Filipe Mira
Centro Hospitalar Medio Tejo, Portugal
Posters & Accepted Abstracts: J Clin Exp Ophthalmol
Introduction & Aim: The diabetic macular edema is the leading cause of blindness in working-age patients. The aim of this study was to evaluate the efficacy of aflibercept in patients with diabetic macular edema unresponsive to anti-VEGF. Material & Methods: Retrospective chart review of patients with diabetic macular edema unresponsive to anti-VEGF switched to aflibercept with 3 months of follow up. All patients have had a minimum of 3 injections of anti-VEGF before switch. Changes in best correct visual acuity, central retinal thickness and frequency of injection were analyzed. Additionally, the percentage of subjects who had vision â�¥ 20/40 (logMAR 0.3) and â�¤ 20/200 (logMAR +1) were evaluated. Results: A total of 32 eyes from 26 diabetic patients were included. The mean age was 65�±10 years old and the majority was female (53%). The mean number of previous anti-VEGF injections was 5.03�±2.19 and the mean number of aflibercept injections at the end of the study was 2.00�±0.00. The central retinal thickness at baseline was 501.47�±150.51 �¼m and 367.97�±124.61 �¼m at 3 months follow up (P=0.000). The best correct visual acuity at baseline was 0.71�±0.36 logMAR and 0.65�±0.33 logMAR at the end of the follow up (P=0.037). At baseline 12.5% of patients had vision 20/40 or better comparing with 25% at 3rd month follow up. At baseline 28.13% of patients had vision 20/200 or inferior comparing with 15.63% at the end of the follow up. Approximately 63% of patients improved vision, 18.75% maintained vision and 18.75% loss vision at the end of the study. Further analysis did not show any correlation between central retinal thicknesses, best correct visual acuity and the number of prior anti-VEGF treatments. Conclusions: Patients with diabetic macular edema unresponsive to previous multiple anti-VEGF injections demonstrate a significant anatomical and functional improvement with switch to aflibercept.
Email: filipemiraferreira@gmail.com